Terms ending in 2040
Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,548,888 | Kras G12C Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 11,634,417 | Protein Tyrosine Phosphatase Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 11,414,404 | Compounds for the Treatment of Braf-Associated Diseases and Disorders In force · High confidence | Array BioPharma Inc. | In force | High confidence | |
| US 11,634,409 | Compounds for the Treatment of Braf-Associated Diseases and Disorders In force · High confidence | Array BioPharma Inc. | In force | High confidence | |
| US 11,884,664 | Protein Tyrosine Phosphatase Inhibitors In force · High confidence | Array BioPharma Inc. | In force | High confidence | |
| US 11,964,989 | Kras G12D Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 12,630,566 | Kras G12D Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 12,747,253 | Kras G12D Inhibitors In force · Medium confidence | Array Biopharma Inc. | In force | Medium confidence | |
| US 11,453,683 | Kras G12D Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.